Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy
A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer
Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.
Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial
Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.
Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial
Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.
Importance of Identifying HER2 Status in Metastatic Colorectal Cancer
Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.
Role of Tucatinib in HER2+ mCRC
Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.
HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates
Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.
Trastuzumab Deruxtecan in HER2+ mCRC
Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.
First-Line Treatment Options for mCRC
After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.
Challenges With Molecular Testing in Metastatic Colorectal Cancer
A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.
Circulating Tumor DNA to Guide Treatment Selection for mCRC
Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.
Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC
Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.
Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)
Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512